PURPOSE: There is clinical need to predict risk of febrile neutropenia before a specific cycle of chemotherapy in cancer patients. METHODS: Data on 3882 chemotherapy cycles in 1089 consecutive patients with lung, breast, and colon cancer from four teaching hospitals were used to construct a predictive model for febrile neutropenia. A final nomogram derived from the multivariate predictive model was prospectively confirmed in a second cohort of 960 consecutive cases and 1444 cycles. RESULTS: The following factors were used to construct the nomogram: previous history of febrile neutropenia, pre-cycle lymphocyte count, type of cancer, cycle of current chemotherapy, and patient age. The predictive model had a concordance index of 0.95 (95 % confidence interval (CI) = 0.91-0.99) in the derivation cohort and 0.85 (95 % CI = 0.80-0.91) in the external validation cohort. A threshold of 15 % for the risk of febrile neutropenia in the derivation cohort was associated with a sensitivity of 0.76 and specificity of 0.98. These figures were 1.00 and 0.49 in the validation cohort if a risk threshold of 50 % was chosen. CONCLUSIONS: This nomogram is helpful in the prediction of febrile neutropenia after chemotherapy in patients with lung, breast, and colon cancer. Usage of this nomogram may help decrease the morbidity and mortality associated with febrile neutropenia and deserves further validation.
PURPOSE: There is clinical need to predict risk of febrile neutropenia before a specific cycle of chemotherapy in cancerpatients. METHODS: Data on 3882 chemotherapy cycles in 1089 consecutive patients with lung, breast, and colon cancer from four teaching hospitals were used to construct a predictive model for febrile neutropenia. A final nomogram derived from the multivariate predictive model was prospectively confirmed in a second cohort of 960 consecutive cases and 1444 cycles. RESULTS: The following factors were used to construct the nomogram: previous history of febrile neutropenia, pre-cycle lymphocyte count, type of cancer, cycle of current chemotherapy, and patient age. The predictive model had a concordance index of 0.95 (95 % confidence interval (CI) = 0.91-0.99) in the derivation cohort and 0.85 (95 % CI = 0.80-0.91) in the external validation cohort. A threshold of 15 % for the risk of febrile neutropenia in the derivation cohort was associated with a sensitivity of 0.76 and specificity of 0.98. These figures were 1.00 and 0.49 in the validation cohort if a risk threshold of 50 % was chosen. CONCLUSIONS: This nomogram is helpful in the prediction of febrile neutropenia after chemotherapy in patients with lung, breast, and colon cancer. Usage of this nomogram may help decrease the morbidity and mortality associated with febrile neutropenia and deserves further validation.
Authors: M S Aapro; D A Cameron; R Pettengell; J Bohlius; J Crawford; M Ellis; N Kearney; G H Lyman; V C Tjan-Heijnen; J Walewski; D C Weber; C Zielinski Journal: Eur J Cancer Date: 2006-06-05 Impact factor: 9.162
Authors: Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff Journal: J Clin Oncol Date: 2006-05-08 Impact factor: 44.544
Authors: Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra Journal: J Clin Oncol Date: 2005-05-23 Impact factor: 44.544
Authors: H Gómez; M Hidalgo; L Casanova; R Colomer; D L Pen; J Otero; W Rodríguez; C Carracedo; H Cortés-Funes; C Vallejos Journal: J Clin Oncol Date: 1998-06 Impact factor: 44.544
Authors: Cesare Gridelli; Matti S Aapro; Sandro Barni; Giordano Domenico Beretta; Giuseppe Colucci; Bruno Daniele; Lucia Del Mastro; Massimo Di Maio; Luigi De Petris; Francesco Perrone; Nick Thatcher; Filippo De Marinis Journal: Crit Rev Oncol Hematol Date: 2007-03-26 Impact factor: 6.312
Authors: I Ray-Coquard; C Borg; Th Bachelot; C Sebban; I Philip; G Clapisson; A Le Cesne; P Biron; F Chauvin; J Y Blay Journal: Br J Cancer Date: 2003-01-27 Impact factor: 7.640
Authors: Jihyoun Lee; Jong Eun Lee; Zisun Kim; Sun Wook Han; Sung Mo Hur; Sung Yong Kim; Min Hyuk Lee; Cheol Wan Lim Journal: Ann Surg Treat Res Date: 2018-04-30 Impact factor: 1.859
Authors: Theis Aagaard; Ashley Roen; Joanne Reekie; Gedske Daugaard; Peter de Nully Brown; Lena Specht; Henrik Sengeløv; Amanda Mocroft; Jens Lundgren; Marie Helleberg Journal: JNCI Cancer Spectr Date: 2018-11-29